- Significantly greater mean declines in HBsAg levels (p
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
On 6ix: 6ix.com/news/arbutus-and-barinthus-bio-announce-new-data-im-prove-ii-trial-showing-addition-0
Watch Arbutus Biopharma's latest callArbutus Biopharma (NASDAQ:ABUS) Q3 2024 Earnings Call · Replay · Nov 6, 2024Read the transcript of Arbutus Biopharma (NASDAQ:ABUS) Q3 2024 Earnings CallArbutus Biopharma Corporation on 6ix
In the deck
Story so far
- Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
- Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
- Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Earlier from Arbutus Biopharma
- Arbutus to Present at Jefferies London Healthcare Conference
- Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
- Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
- Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Later from Arbutus Biopharma
- Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
- Arbutus Provides 2025 Corporate and Financial Update
- Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
- Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
- Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Follow Arbutus Biopharma into a list and get an email when it puts out news.
Follow Arbutus Biopharma